Inherited Retinal Disease in China: approved, in trials, and only sold
This is the page on this site most likely to end with don't come. Retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and Leber hereditary optic neuropathy are the conditions where China is searched for hardest — and they are also the conditions where the gap between what a Chinese hospital can lawfully give you and what somebody will happily take your money for is at its widest. So this page separates three things that get deliberately blurred: one therapy that is genuinely purchasable, several that are real science but not products, and a category that is neither.
These are gene diseases, not eye diseases, and every option on this page is keyed to a specific gene. If you do not yet know which gene you carry, nothing here can be applied to you — and anyone offering to treat you without asking is not offering what they say they are. Candidacy for any of it is decided by a treating specialist after examination and genetic confirmation, never by a website and never by a coordinator.
Three doors, and only one of them sells anything
China does not have a single regulatory answer for inherited retinal disease. It has three parallel routes with completely different rules, and most of the confusion overseas patients run into comes from press coverage that reports one of them as though it were another.
| Route | What it means | Who it can reach | What it costs you |
|---|---|---|---|
| National NMPA licence | A marketing authorisation valid in hospitals across the country | Anyone meeting the label | No IRD gene therapy holds one |
| Boao Lecheng zone access 博鳌乐城 |
Hainan's pilot zone, where a medicine licensed by an overseas regulator may be used with Hainan authority approval, ahead of national approval | Patients who travel to the zone and are accepted by the hospital's team | Published price, self-pay |
| Clinical trial | An investigational product under a cleared IND, at named sites, under a protocol | Patients who meet inclusion criteria and are recruited by the site | Nothing — trials do not charge |
The fourth thing — a clinic that will infuse something into you next week for a fee — is not a route. It is dealt with further down, and it is the reason this page exists in the shape it does.
The one therapy you can actually buy, and the number that decides it
Gene therapy for biallelic RPE65-associated inherited retinal dystrophy is available at Ruijin Hospital's Hainan campus inside the Boao Lecheng zone. It was reported as the first gene therapy in a batch of treatments released around the 2025 Boao congress, and it reaches patients through the zone's early-access mechanism rather than a national licence. RPE65 therapy is the only inherited retinal disease treatment approved by any major regulator worldwide, so the zone is importing a real, licensed medicine — not improvising one.
| Item | Detail |
|---|---|
| Indication | Confirmed biallelic RPE65 mutation with viable remaining retinal cells |
| Site | Ruijin Hospital, Hainan campus — Boao Lecheng pilot zone |
| Published price | ¥480,000 per single eye |
| Approximate USD | ≈ US$67,100 per eye |
| Both eyes | ≈ ¥960,000 / US$134,200 |
| Payment | Self-pay; no Chinese public insurance route for overseas patients |
The yuan figure is the published one and the dollar figure is a conversion at mid-August 2026 rates, so treat the dollar column as indicative and the yuan column as the number. It covers the therapy, not the genetic testing, screening examinations, imaging, travel, accommodation or follow-up, and it is a programme price rather than a quotation to you.
In a Chinese tertiary centre for genetic eye disease, exome sequencing found RPE65 mutations in about 0.8% of hereditary retinal degeneration cases (18 of 2,133), and about 3.0% of Leber congenital amaurosis cases (8 of 269). Other Chinese series have put RPE65 as low as 1% of LCA. Across Western cohorts the gene runs materially higher. So the one product China sells fits well under one patient in a hundred with inherited retinal degeneration — and it is rarer in Chinese patients than in the populations the therapy was developed against.
That is the whole decision for most people reading this. If your genetic report names RPE65 on both alleles, Lecheng is a real option and worth pricing against access at home, where the same therapy is licensed in the United States, the European Union and Japan and may be reimbursed. If it names anything else, the Lecheng programme is not for you and no amount of enquiry will change that.
LHON: where China genuinely leads, and why you still cannot buy it
If there is one area where China has accumulated something the rest of the world has not, it is Leber hereditary optic neuropathy — the mitochondrial condition that takes central vision from young adults, usually men, usually over weeks, usually in both eyes in sequence.
NR082 (rAAV2-ND4), developed by Neurophth, delivers a mitochondria codon-optimised ND4 gene by intravitreal injection for LHON caused by ND4 mutation. Its development record is unusual:
| Milestone | Detail |
|---|---|
| US FDA orphan drug designation | September 2020 |
| China CDE IND clearance | March 2021 — reported as China's first AAV2 gene therapy IND |
| China breakthrough therapy designation | July 2022 |
| Prior investigator-initiated experience | 186 patients across three IITs |
| Longest reported follow-up | up to 90 months in the first IIT |
| Registration study | Phase 1/2/3 GOLD (NCT04912843); dose 4.5×10⁹ vg in 0.05 mL per eye |
| Status | Enrolment and dosing complete — not approved |
One hundred and eighty-six treated patients with follow-up measured in years is, as far as we can establish, the largest and longest body of LHON gene therapy experience anywhere. The investigator-initiated work reported that intravitreal rAAV2-ND4 was well tolerated and could improve visual acuity. That is a genuine reason to pay attention to China on this condition.
Completing enrolment is the point at which a trial stops taking patients. An unapproved investigational product cannot be sold, prescribed or administered outside its protocol. There is, today, no lawful way to receive NR082 in China as a paying overseas patient — and if someone offers you one, that offer is the problem, not the solution.
The China-developed RPE65 programme, and what it is really claiming
Running alongside the imported product is a domestic one. HG004, from Shanghai-based HuidaGene Therapeutics, is an AAV gene therapy for RPE65-associated inherited retinal dystrophy — reported as the first China-developed AAV gene therapy medicine evaluated in a multinational, multicentre master-protocol trial, with IND clearance from both China's NMPA and the US FDA, plus FDA orphan drug and rare paediatric disease designations.
The claim worth understanding is a technical one rather than a marketing one. Patients enrolled in a Chinese investigator-initiated trial from the end of 2022, who were progressing toward complete blindness, were reported to have substantial restoration of vision at vector doses around 25 times lower than the approved AAV2-hRPE65 product. Dose matters in subretinal gene therapy because the volume and the immune load are what the eye has to tolerate; a therapy that works at a fraction of the dose is a meaningfully different proposition, not a cheaper copy.
It is also, still, not approved. It is in trials. The same rule applies: a trial does not take payment and does not take walk-ins.
Can an overseas patient get into a Chinese trial?
Occasionally — but almost never by arriving and asking, and the mechanism is worth understanding because it explains why "we can get you into the trial" is such a reliable warning sign.
- Trials in China are usually run to support a Chinese marketing application. The dossier is built for the NMPA, so the population is built for the NMPA.
- Sponsors often apply nationality or ethnicity criteria, on the reasoning that ethnic differences and drug metabolism bear on the registration package. That is a protocol-level restriction, not a preference a coordinator can waive.
- Rare-disease protocols relax it more often, because the population is small and the inclusion criteria are biological — you carry the mutation or you do not. This is the crack through which it sometimes happens.
- Sites recruit from their own clinics. A tertiary genetic eye service enrols the patients already under its care. There is no queue you join from abroad.
- Nobody pays to be in a trial. Sponsors fund trials. A request for a fee means what you are being offered is not the trial.
If you want to pursue this properly, the route is: obtain a molecular diagnosis, then have your own retinal specialist write to the investigator named on the trial registration with your genetic report and clinical record. If there is a route in, that is where it opens. It is slow, it is usually a no, and it costs nothing to try.
What is sold, and is not treatment
Retinitis pigmentosa is one of the most heavily targeted conditions in the direct-to-consumer cell therapy market worldwide — and China's association with the phrase "stem cells", earned or otherwise, means those offers reach patients researching China specifically.
The position is not ambiguous. No cell-based therapy is approved for any inherited retinal disease, in China or anywhere else. The published literature on unregulated fee-for-service cell clinics describes a consistent pattern: direct-to-consumer advertising, high out-of-pocket fees, and cell preparations that have not been properly characterised or purified. Retinal cell therapy is a serious research field with real trials in it; that is precisely what makes the commercial imitation of it effective.
1. Which gene is this for, and what will you do if my report names a different one?
A real programme is gene-specific and will decline you.
2. What is the trial registration number, and on which registry?
Then look it up yourself.
3. Who is the principal investigator, and at which hospital?
A named clinician at a named institution, or nothing.
4. Is there a control arm, and how is outcome measured?
"Everyone gets treated and we ask how you feel" is not a study.
5. What am I being asked to pay, and for what?
Trials do not bill for the investigational product.
6. What is the published result, and where?
Ask for a citation. Testimonials are not results.
One further tell, specific to this disease: inherited retinal disease progresses slowly and fluctuates, and patients often perceive better vision after any intervention involving attention, dilation, better lighting advice and hope. That is exactly why an uncontrolled series of happy patients proves nothing, and why the honest programmes run controls.
The genes that actually cause this, and what exists for each
Inherited retinal disease has been associated with roughly 300 genes, of which more than 90 can cause retinitis pigmentosa. In reported Chinese cohorts the distribution is concentrated: the twenty most frequently implicated genes account for about 71.8% of molecularly diagnosed families.
| Gene | Share of molecularly diagnosed Chinese families | Approved therapy anywhere |
|---|---|---|
| ABCA4 | 20.8% | None |
| USH2A | 9.1% | None |
| RPGR | 5.1% | None |
| RPE65 | ≈0.8% of hereditary retinal degeneration | Yes — the therapy described above |
Read that table honestly and it says something uncomfortable: the three commonest causes of inherited retinal disease in Chinese patients have no approved treatment anywhere in the world, and the one gene that does have a product is among the rarest. No destination changes that. It is not a reason to distrust Chinese medicine; it is the current state of the field, and it is the same in London, Boston and Tokyo.
For context on burden rather than treatment: retinitis pigmentosa has been reported to account for roughly 49% of inherited retinal disease diagnoses in a recent Chinese patient series, with nearly half of patients reporting onset before school age, and that series described substantial delays in diagnosis and limited access to genetic testing. Population prevalence estimates for RP in China vary widely by method — on the order of 1 in 3,000 by conventional estimate, with one population-based study of older adults in northern China implying a much larger national figure. Prevalence estimates of that spread should be read as an indication that the condition is common enough to be badly served, not as a count.
If you have no genetic diagnosis, that is the useful trip
Molecular diagnosis succeeds in roughly 72% of clinically suspected retinitis pigmentosa cases in reported Chinese cohorts — around 80% where onset was at or before age five, and around 66% where onset was at seventeen or later. A meaningful minority therefore end with no answer, which is itself worth knowing before you spend on it.
What a proper genetic eye service should produce, and what you should insist on receiving in writing:
- A panel or exome result naming the gene, the variants and the zygosity — not "a mutation was found". Biallelic versus monoallelic is the difference between eligible and not.
- Variant classification against ACMG criteria, so you know whether the finding is pathogenic, likely pathogenic, or a variant of uncertain significance.
- Segregation testing in your parents where possible, which is often what converts an uncertain result into a usable one.
- Structural imaging — OCT and autofluorescence — because eligibility for any retinal gene therapy depends on there being viable cells left to rescue, not on the genotype alone.
- The report in a language your specialist reads, with the raw variant nomenclature included so it can be re-interpreted later. Gene classifications change; your report should survive that.
This work does not require China. It is available in most countries with a genetic eye service, it is far cheaper than any therapy, and it is the only step that is useful regardless of what becomes available in the next ten years. If you do it in China as part of a wider visit, the same five requirements apply, and our page on records and insurance documentation from abroad covers getting the paperwork into a form your specialist at home can act on.
What we are not going to claim
Some things about this page's subject we could not establish, and we would rather name them than paper over them:
- We have no partner arrangement for the Lecheng RPE65 programme and no ability to secure a place in it. The published price is reproduced here as published; we did not obtain a quotation and we do not take a fee on it.
- We could not verify current programme availability, waiting times, or whether overseas patients are being accepted at the Hainan site. Zone approvals are batch-based and can change. Confirm directly with the hospital before making any plan around it.
- We have not seen Phase III efficacy data for NR082. Enrolment completion is a public fact; outcomes are not yet, and the earlier investigator-initiated results are not a substitute for them.
- We are not naming a Chinese hospital as best for inherited retinal disease. This is a field where the institution matters less than the molecular diagnosis, and a ranking would imply a choice that most readers do not have.
- We do not offer, arrange or refer for cell therapy of any kind for retinal disease.
If your genetics point somewhere ordinary and treatable — cataract at an unusual age, a refractive problem alongside a stable dystrophy, a retinal complication that has its own management — those are things we can genuinely help with, and they are covered on what eye surgery costs in China and how the major eye hospitals compare.
Frequently asked questions
Is there an approved gene therapy for inherited retinal disease in China?
Not nationally. No gene therapy for inherited retinal disease holds an NMPA marketing licence. One can be bought: RPE65 gene therapy at Ruijin Hospital's Hainan campus inside the Boao Lecheng pilot zone, where medicines licensed by overseas regulators may be used with Hainan authority approval. It was reported as the first gene therapy in a batch released around the 2025 Boao congress. That is zone-level early access, not national approval, and it exists in one place.
How much does RPE65 gene therapy cost in China?
The published figure for the Hainan programme is ¥480,000 per single eye — roughly US$67,100 at mid-August 2026 rates, so about ¥960,000 for both. It is self-pay, it excludes genetic testing, screening, travel and follow-up, and it is a programme price researched August 2026 rather than a quotation. Before treating it as a saving, price the same licensed therapy at home: it is reimbursed in some health systems, which can make the domestic route cheaper despite the sticker.
I have retinitis pigmentosa — can I be treated in China?
Almost certainly not with anything licensed. RP is caused by more than ninety genes and the purchasable Chinese therapy addresses one, RPE65, which accounted for about 0.8% of hereditary retinal degeneration in a Chinese tertiary genetic eye centre. The commonest genes in Chinese patients — ABCA4, USH2A, RPGR — have no approved therapy anywhere. Anyone willing to treat your RP without asking which gene you carry is not offering gene therapy.
Is China ahead of the West on LHON?
On accumulated patient experience, yes. NR082 was evaluated in three investigator-initiated trials involving 186 patients with follow-up reported up to 90 months in the first — the largest and longest such record we can find anywhere. It holds a US orphan drug designation, a China breakthrough therapy designation, and cleared China's first AAV2 gene therapy IND in March 2021. None of that makes it purchasable. It is not approved, and Phase III enrolment is closed.
Can I join a Chinese gene therapy trial as a foreigner?
Rarely, and never by flying in to ask. Chinese registration trials support a Chinese marketing application, sites recruit from their own clinic populations, and sponsors often apply nationality or ethnicity criteria. Rare-disease protocols relax those more often, so it is not impossible. The route is your own specialist writing to the named investigator with your genetic report, before any travel. If money is requested, it is not a trial.
What about stem cells for retinitis pigmentosa?
No cell-based therapy is approved for any inherited retinal disease anywhere. Unregulated fee-for-service cell clinics are a documented international problem — direct-to-consumer advertising, large out-of-pocket fees, cell preparations that have not been properly characterised. Retinal cell therapy is a legitimate research field, which is exactly what makes the commercial imitation persuasive. Use the six questions on the page; a real programme answers all six in writing and often declines you.
My child has Leber congenital amaurosis. Where do I start?
With the gene, and quickly, because diagnostic yield is highest in early-onset disease — around 80% where onset was at or before age five. If the result is biallelic RPE65, a licensed therapy exists and there are several routes to it including, but not only, Hainan; discuss it with a paediatric retinal genetics service. If it is one of the many other LCA genes, the honest answer today is that no approved therapy exists, and the useful actions are registry enrolment, low-vision support and periodic re-review as the field moves.
Should I travel to China for inherited retinal disease?
For most readers, no, and we would rather say it than sell a trip. The narrow exceptions are a confirmed biallelic RPE65 diagnosis where Lecheng is worth pricing against access at home, and a documented invitation from a trial investigator. Absent either, the trip worth taking is a diagnostic one, and it can usually be taken closer to home. We would rather you came back to us in three years with a reason than went now without one.